Securities
Oct. 27, 2016
$95M Amgen investor suit approved
A $95 million settlement of investor claims against biotech company Amgen Inc received final approval on Tuesday, marking the end of a decade of precedent-setting litigation on class certification requirements in securities fraud cases that reached the U.S. Supreme Court in 2013.
Daily Journal Staff Writer
LOS ANGELES — A $95 million settlement of investor claims against biotech company Amgen Inc. received final approval on Tuesday, marking the end of a decade of precedent-setting litigation on class certification requirements in securities fraud cases that reached the U.S. Supreme Court in 2013.
In less than five minutes, U.S. District Judge Philip S. Gutierrez called the case, expres...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In